Who is sponsoring NCT00640185?

NCT00640185 is sponsored by AbbVie (prior sponsor, Abbott).

What drugs are being tested in NCT00640185?

Interventions in NCT00640185: ABT-089, Placebo.

What condition does NCT00640185 study?

NCT00640185 studies Attention-Deficit/Hyperactivity Disorder.

Is NCT00640185 still recruiting?

NCT00640185 is currently completed. Last updated 10 January 2013.

Last reviewed 2013-01-10 · How we verify

NCT00640185

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Pilot, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety, Tolerability and Efficacy of 40 mg QD and 80 mg QD ABT-089 in Adults With Attention Deficit-Hyperactivity Disorder (ADHD)

Completed Phase 2 Last updated 10 January 2013

What this trial tests

Phase 2 trial testing ABT-089 in Attention-Deficit/Hyperactivity Disorder in 160 participants. Completed in 1 August 2008.

Timeline

1 March 2008

Primary endpoint
1 August 2008

1 August 2008

Quick facts

Lead sponsor	AbbVie (prior sponsor, Abbott)
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	160
Start date	1 March 2008
Primary completion	1 August 2008
Estimated completion	1 August 2008
Sites	12 locations across United States

Drugs / interventions tested

ABT-089 — full drug profile →
Placebo

Conditions studied

Attention-Deficit/Hyperactivity Disorder — all drugs for Attention-Deficit/Hyperactivity Disorder →

Sponsor

AbbVie (prior sponsor, Abbott) — full company profile →

Who can join

Adults 18 to 60, any sex, with Attention-Deficit/Hyperactivity Disorder. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

CAARS: Inv Total Score
Time frame: Screening, Day -1, Day 7, Day 14, Day 28, Day 42 and Day 56

Sponsor's own description

The purpose of this study is to test if the investigational medication ABT-089 is a safe and effective treatment for adults with Attention-Deficit/Hyperactivity Disorder (ADHD).

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Nicotinic receptors in neurodegeneration.
Posadas I, López-Hernández B, Ceña V. · · 2013 · cited 79× · PMID 24179465 · DOI 10.2174/1570159x11311030005
A randomized pilot study of the efficacy and safety of ABT-089, a novel α4β2 neuronal nicotinic receptor agonist, in adults with attention-deficit/hyperactivity disorder.
Bain EE, Apostol G, Sangal RB, Robieson WZ, et al · · 2012 · cited 16× · PMID 22795204 · DOI 10.4088/jcp.10m06719

Verify or expand the search:

Other recruiting trials for Attention-Deficit/Hyperactivity Disorder

Currently open trials in the same condition.

NCT07327775 — Fibromyalgia Disease Burden in Mothers of Children With Attention-Deficit/Hyperactivity Disorder · recruiting

Other AbbVie (prior sponsor, Abbott) trials

Trials by the same sponsor.

NCT01609933 — A Study to Evaluate the Safety and Effect of Treatment With Experimental Antiviral Drugs in Combination With Peginterfer · Phase 2 · completed
NCT01657799 — Comparison of Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Adults With Brain Metastases · Phase 2 · completed
NCT01736189 — Assessment of Clinical Effectiveness and Safety of Adalimumab and High Dose Methotrexate in Routine Clinical Practice · completed
NCT01620528 — A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Assoc · Phase 3 · completed
NCT01506947 — A Pilot Clinical Study Evaluating the Effect of Parathyroid Hormone (PTH) Lowering On Erythropoietin Consumption in Calc · Phase 4 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00640185 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AbbVie (prior sponsor, Abbott)
Last refreshed: 10 January 2013

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00640185.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing